Effects of common topical antiglaucoma medications on the ocular surface, eyelids and periorbital tissue

Drugs and Aging

Volumn 28, Issue 4, 2011, Pages 267-282

  Servat, J Javier ^a   Bernardino, C Robert ^b  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b Vantage Eye Center   (United States)

Author keywords

Alpha adrenergic receptor agonists; Apraclonidine; Beta adrenergic receptor antagonists; Bimatoprost; Brimonidine; Brinzolamide; Carbonic anhydrase inhibitors; Cholinergic receptor agonists; Dorzolamide; Elderly; Glaucoma; Latanoprost; Pilocarpine; therapeutic use; Travoprost; treatment

Indexed keywords

ANTIGLAUCOMA AGENT; APRACLONIDINE; BENZALKONIUM CHLORIDE; BENZODODECINIUM; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BRIMONIDINE; BRINZOLAMIDE; CARBACHOL; DEMECARIUM; DIISOPROPYL FLUOROPHOSPHATASE; DORZOLAMIDE; DRUG PRESERVATIVE; ECOTHIOPATE IODIDE; LATANOPROST; LEVOBUNOLOL; PILOCARPINE; POLYQUATERNIUM 1; PURITE; SOFZIA; TIMOLOL; UNCLASSIFIED DRUG;

ALLERGENICITY; ALLERGIC REACTION; APHAKIA; AQUEOUS HUMOR; BACTERIOSTASIS; BIOMICROSCOPY; BLEPHARITIS; BLEPHAROCONJUNCTIVITIS; BLURRED VISION; BURNING SENSATION; CHEMOSIS; CLOSED ANGLE GLAUCOMA; CONJUNCTIVAL HYPEREMIA; CONJUNCTIVITIS; CONTACT DERMATITIS; CORNEA; CROSS REACTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECTROPION; ECZEMA; ENDOPLASMIC RETICULUM; EPIPHORA; ERYTHEMA MULTIFORME; EYE BURNING; EYE DISCOMFORT; EYE DISEASE; EYE IRRITATION; EYE REDNESS; EYE STINGING; EYELID; EYELID DISEASE; EYELID ERYTHEMA; EYELID RETRACTION; FOREIGN BODY REACTION; GLAUCOMA; HEALTH CARE COST; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; KERATINIZATION; KERATITIS; KERATOEPITHELIOPATHY; LACRIMAL APPARATUS; LACRIMAL DUCT OCCLUSION; LACRIMAL FLUID; LICHEN PLANUS; MUSCLE SPASM; NONHUMAN; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; OPTIC NERVE; OPTIC NERVE DISEASE; ORBIT; OUTCOME ASSESSMENT; PATIENT MONITORING; PATIENT SELECTION; PHOTOPHOBIA; PRIORITY JOURNAL; PSEUDOPHAKIA; PUNCTATE KERATITIS; REVIEW; SIDE EFFECT; SKIN ALLERGY; SQUAMOUS CELL METAPLASIA; TACHYPHYLAXIS; TOXIC EPIDERMAL NECROLYSIS; TRABECULOPLASTY; TREATMENT DURATION; VASOCONSTRICTION; VISUAL IMPAIRMENT;

ADMINISTRATION, TOPICAL; ADRENERGIC ALPHA-AGONISTS; ADRENERGIC BETA-AGONISTS; CARBONIC ANHYDRASE INHIBITORS; CHOLINERGIC AGENTS; CONJUNCTIVA; CORNEA; EYE; EYE DISEASES; EYELIDS; GLAUCOMA, OPEN-ANGLE; HUMANS; PATIENT COMPLIANCE; PROSTAGLANDINS; TREATMENT OUTCOME;

EID: 79953183017     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11588830-000000000-00000     Document Type: Review

References (191)

1. Friedman DS, Wilson MR, Liebmann JM, et al. An evidencebased assessment of risk factors for the progression of ocular hypertension and glaucoma. Am J Ophthalmol 2004;138(3 Suppl.): S19-31 (Pubitemid 39195354)
2. Friedman DS, Wolfs RC, O'Colmain BJ, et al. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol 2004;122(4):532-8 (Pubitemid 38456289)
3. Ishibashi T, Yokoi N, Kinoshita S. Comparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chloride. J Glaucoma 2003 Dec; 12(6):486-90 (Pubitemid 37494177)
4. Liesegang TJ. Conjunctival changes associated with glaucoma therapy: implications for the external disease consultant and the treatment of glaucoma. Cornea 1998 Nov; 17(6):574-83 (Pubitemid 28511900)
5. Mietz H, Niesen U, Krieglstein GK. The effect of preservatives and antiglaucomatous medication on the histopathology of the conjunctiva. Graefes Arch Clin Exp Ophthalmol 1994 Sep; 232(9):561-5 (Pubitemid 24249226)
6. Baudouin C, Pisella PJ, Fillacier K, et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology 1999 Mar; 106(3):556-63 (Pubitemid 30191592)
7. Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther 2001;18(5):205-15 (Pubitemid 33131188)
8. Albietz JM, Bruce AS. The conjunctival epithelium in dry eye subtypes: effect of preserved and non-preserved topical treatments. Curr Eye Res 2001 Jan; 22(1):8-18 (Pubitemid 32679487)
9. Nenciu A, Stefan C, Ardelean C. Structural and immunohistochemical changes of conjunctiva induced by topical glaucoma medication. Oftalmologia 2004;48(1):35-42
10. Doǧan AS, Orhan M, Söylemezoǧlu F, et al. Effects of topical antiglaucoma drugs on apoptosis rates of conjunctival epithelial cells in glaucoma patients. Clin Exp Ophthalmol 2004 Feb; 32(1):62-6 (Pubitemid 38344286)
11. Manni G, Centofanti M, Oddone F, et al. Interleukin-1beta tear concentration in glaucomatous and ocular hypertensive patients treated with preservative-free nonselective beta-blockers. Am J Ophthalmol 2005 Jan; 139(1):72-7 (Pubitemid 40094842)
12. Pisella PJ, Debbasch C, Hḿrd P, et al. Conjunctival proinflammatory and proapoptotic effects of lt́noprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest Ophthalmol Vis Sci 2004;45:1360-8 (Pubitemid 38859312)
13. Furrer P, Mayer JM, Plazonnet B, et al. Ocular tolerance of absorption enhancers in ophthalmic prepŕtions. AAPS PharmSci 2002;4(1):E2
14. Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol 2002 Apr; 86(4):418-23 (Pubitemid 34293291)
15. Champeau EJ, Edelhauser HF. Effect of ophthalmic preservatives on the ocular surface: conjunctival and corneal uptake and distribution of benzalkonium chloride and chlorhexidine digluconate. In: Holly F, Lamberts D, Mac Keen D, editors. The preocular tear film in health, disease, and contact lens wear. Lubbock (TX): Dry Eye Institute Inc., 1998:292-302
16. Scholz M, Lin JC, Lee VHL, et al. Pilocarpine permeability across ocular tissues and cell cultures: influence of formulation pŕmeters. J Ocul Pharmacol Ther 2002;18:455-68 (Pubitemid 37420254)
17. Eleftheriadis H, Cheong M, Sandeman S, et al. Corneal toxicity secondary to inadvertent use of benzalkonium chloride preserved viscoelastic material in ct́ract surgery. Br J Ophthalmol 2002;86:299-305 (Pubitemid 34206344)
18. Cha SH, Lee JS, Oum BS, et al. Corneal epithelial cellular dysfunction from benzalkonium chloride (BAC) in vitro. Clin Exp Ophthalmol 2004;32:180-4
19. Debbasch C, Brignole F, Pisella PJ, et al. Quaternary ammonium and other preservatives' contribution in oxidative stress and apoptosis on Chang conjunctival cells. Invest Ophthalmol Vis Sci 2001;42:642-52 (Pubitemid 32206903)
20. De Saint Jean M, Debbasch C, Brignole F, et al. Toxicity of preserved and unpreserved antiglaucoma topical drugs in an in vitro model of conjuctival cells. Curr Eye Res 2000;20:85-94 (Pubitemid 30099159)
21. Katz LJ. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma 2002;11:119-26 (Pubitemid 34298592)
22. Baudouin C. Mechanism of failure in glaucoma filtrating surgery: a consequence of antiglaucomatous drugs? Int J Clin Pharmacol Res 1996; XVI (1):29-41 (Pubitemid 27013506)
23. Kahook MY. Travoprost Z ophthalmic solution with sofZia: clinical safety and efficacy. Expert Rev Ophthalmol 2007;2:363-8
24. Lui AC, Netto AL, Silva CB, et al. Antimicrobial efficacy assessment of multi-use solution to disinfect hydrophilic contact lens, in vitro. Arq Bras Oftalmol 2009 Sep-Oct; 72(5):626-30
25. Codling CE, Hann AC, Maillard JY, et al. An investigation into the antimicrobial mechanisms of action of two contact lens biocides using electron microscopy. Cont Lens Anterior Eye 2005 Dec; 28(4):163-8 (Pubitemid 43024697)
26. Codling CE, Maillard JY, Russell AD. Aspects of the antimicrobial mechanisms of action of a polyquaternium and an amidoamine. J Antimicrob Chemother 2003 May; 51(5):1153-8 (Pubitemid 36622071)
27. Ammar DA, Noecker RJ, Kahook MY. Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells. Adv Ther 2010 Nov; 27(11):837-45
28. Yḿzaki S, Nanno M, Kimura T, et al. Effects of switching to SofZia-preserved travoprost in patients who presented with superficial punctate keratopathy while under treatment with lt́noprost. Jpn J Ophthalmol 2010 Jan; 54(1):7-14
29. Goldberg I, Goldberg H. Betaxolol eye drops: a clinical trial of safety and efficacy. Aust N Z J Ophthalmol 1995 Feb; 23(1):17-24
30. Battershill PE, Sorkin EM. Ocular metipranolol: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in glaucoma and ocular hypertension. Drugs 1988;36:601-15
31. Wandel T, Chŕp AD, Lewis RA, et al. Glaucoma treatment with once-daily levobunolol. Am J Ophthalmol 1986;101:298-304 (Pubitemid 16132655)
32. ®) in Germany. Ophthalmologica 1988;197:90-6
33. de Groot AC, van Ginkel CJ, Bruynzeel DP, et al. Contact allergy to eyedrops containing beta-blockers. Ned Tijdschr Geneeskd 1998 May 2; 142(18):1034-6 (Pubitemid 28204786)
34. Corazza M, Virgili A, Mantovani L, et al. Allergic contact dermatitis from cross-reacting beta-blocking agents. Contact Dermatitis 1993 Mar; 28(3):188-9 (Pubitemid 23093374)
35. O'Donnell BF, Foulds IS. Contact allergy to beta-blocking agents in ophthalmic prepŕtions. Contact Dermatitis 1993 Feb; 28(2):121-2 (Pubitemid 23075036)
36. Cameli N, Vicenzi C, Tosti A. Allergic contact conjunctivitis due to timolol in eyedrops. Contact Dermatitis 1991 Aug; 25(2):129-30
37. Fernandez-Vozmediano JM, Blasi NA, Romero-Cabrera MA, et al. Allergic contact dermatitis to timolol. Contact Dermatitis 1986 Apr; 14(4):252 (Pubitemid 16114449)
38. Romaguera C, Grimalt F, Vilaplń J. Contact dermatitis by timolol. Contact Dermatitis 1986 Apr; 14(4):248 (Pubitemid 16114446)
39. Erdmann S, Hertl M, Merk HF. Contact dermatitis from levobunolol eyedrops. Contact Dermatitis 1999 Jul; 41(1):44-6 (Pubitemid 29324894)
40. van der Meeren HL, Meurs PJ. Sensitization to levobunolol eyedrops. Contact Dermatitis 1993 Jan; 28(1):41-2 (Pubitemid 23012826)
41. Buquicchio R, Foti C, Cassano N, et al. Allergic contact dermatitis from timolol complicating choroidal melanomarelated glaucoma. Eur J Dermatol 2009 Jan-Feb; 19(1):74-5
42. Jappe U, Uter W, Menezes de Pádua CA, et al. Allergic contact dermatitis due to beta-blockers in eye drops: a retrospective ńlysis of multicentre surveillance dt́ 1993-2004. Acta Derm Venereol 2006;86(6):509-14 (Pubitemid 44950743)
43. Kĺvĺ M, Statham BN. Allergic contact dermatitis from timolol and dorzolamide eye drops. Contact Dermatitis 2006 Jun; 54(6):345 (Pubitemid 43886536)
44. Nino M, Napolitano M, Scalvenzi M. Allergic contact dermatitis due to the beta-blocker betaxolol in eyedrops, with cross-sensitivity to timolol. Contact Dermatitis 2010 May; 62(5):319-20
45. Airaksinen PJ, Valle O, Takki KK, et al. Timolol treatment of chronic open-angle glaucoma and ocular hypertension: a 2.5 year multicenter study. Graefes Arch Clin Exp Ophthalmol 1982;219:68-71 (Pubitemid 12048172)
46. Fiore PM, Jacobs IH, Goldberg DB. Drug-induced pemphigoid: a spectrum of diseases. Arch Ophthalmol 1987 Dec; 105(12):1660-3
47. Akingbehin T, Villd́ JR, Walley T. Metipranolol-induced adverse reactions: I. The rechallenge study. Eye 1992;6(3):277-9 (Pubitemid 23055166)
48. Mullins RJ, Lones R, Dutta B. Lichenoid drug eruption secondary to topical timolol and dorzolamide eye-drops. Austrĺs J Dermatol 2004 May; 45(2):151-2 (Pubitemid 38607936)
49. Seider N, Miller B, Beiran I. Topical glaucoma therapy as a risk factor for nasolacrimal duct obstruction. Am J Ophthalmol 2008 Jan; 145(1):120-3
50. Kashkouli MB, Rezaee R, Nilforoushan N, et al. Topical antiglaucoma medications and lacrimal drainage system obstruction. Ophthal Plast Reconstr Surg 2008 May-Jun; 24(3):172-5
51. McNab AA. Lacrimal cńlicular obstruction associated with topical ocular medication. Aust N Z J Ophthalmol 1998 Aug; 26(3):219-23 (Pubitemid 28372498)
52. Narioka J, Ohashi Y. Effects of beta-adrenergic antagonist on width of nasolacrimal drainage system lumen. J Ocul Pharmacol Ther 2007 Oct; 23(5):467-75 (Pubitemid 350214007)
53. Van Buskirk EM. Corneal anesthesia after timolol maleate therapy. Am J Ophthalmol 1979 Oct; 88(4):739-43
54. Weissman SS, Asbell PA. Effects of topical timolol (0.5%) and betaxolol (0.5%) on corneal sensitivity. Br J Ophthalmol 1990 Jul; 74(7):409-12 (Pubitemid 20210928)
55. Trope GE, Liu GS, Basu PK. Toxic effects of topically administered Betǵn, Betoptic, and Timoptic on regenerating corneal epithelium. J Ocul Pharmacol 1988 Winter; 4(4):359-66 (Pubitemid 19059558)
56. Pozarowska D, Pozarowski P, Darzynkiewicz Z. Cytometric assessment of cytostatic and cytotoxic effects of topical glaucoma medications on human epithelial corneal line cells. Cytometry B Clin Cytom 2010 Mar; 78(2):130-7
57. Niiya A, Yokoi N, Matsumoto Y, et al. Effect of betablocker eyedrops on corneal epithelial barrier function. Ophthalmologica 2000 Sep-Oct; 214(5):332-6
58. Ishibashi T, Yokoi N, Kinoshita S. Comparison of the effects of topical levobunolol and timolol solution on the human ocular surface. Cornea 2003 Nov; 22(8):709-15 (Pubitemid 37337598)
59. Strempel I. The influence of topical beta-blockers on the breakup time. Ophthalmologica 1984;189(3):110-5 (Pubitemid 14042590)
60. Shimźki J, Hńda K, Yagi Y, et al. Changes in ocular surface caused by antiglaucomatous eyedrops: prospective, randomised study for the comparison of 0.5% timolol v 0.12% unoprostone. Br J Ophthalmol 2000 Nov; 84(11):1250-4
61. Inoue K, Okugẃ K, Kato S, et al. Ocular factors relevant to anti-glaucomatous eyedrop-related keratoepitheliopathy. J Glaucoma 2003 Dec; 12(6):480-5 (Pubitemid 37494176)
62. Baldone JA, Hankin JS, Zimmerman TJ. Allergic conjunctivitis associated with timolol therapy in an adult. Ann Ophthalmol 1982 Apr; 14(4):364-5 (Pubitemid 12119367)
63. Steuhl KP, Knorr M, Frohn A, et al. Effect of anti-glaucoma eyedrops on cell differentiation of the conjunctiva. Fortschr Ophthalmol 1991;88(6):865-9
64. Hiraoka T, Daito M, Kiuchi T, et al. Time course of changes in contrast sensitivity function after application of antiglaucomatous eyedrops. Nippon Ganka Gakkai Zasshi 2009 Dec; 113(12):1139-44
65. Crichton AC. Update in glaucoma - the new pharmacotherapies: brimonidine versus apraclonidine. Can J Ophthalmol 1998;33:254-5
66. Lee DA, Topper JE, Brubaker RF. Effect of clonidine on aqueous humor flow in normal human eyes. Exp Eye Res 1984 Mar; 38(3):239-46 (Pubitemid 14148152)
67. Ghŕgozloo NZ, Relf SJ, Brubaker RF. Aqueous flow is reduced by the alpha-adrenergic agonist, apraclonidine hydrochloride (ALO 2145). Ophthalmology 1988 Sep; 95(9):1217-20
68. Krupin T, Stank T, Feitl ME. Apraclonidine pretreatment decreases the acute intraocular pressure rise after laser trabeculoplasty or iridotomy. J Glauc 1992;1:79-86
69. Holmwood PC, Chase RD, Krupin T, et al. Apraclonidine and argon laser trabeculoplasty. Am J Ophthalmol 1992 Jul; 114(1):19-22
70. Threlkeld AB, Assalian AA, Allingham R, et al. Apraclonidine 0.5%versus 1%for controlling intraocular pressure elevation after argon laser trabeculoplasty. Ophthalmic Surg Lasers 1996;27:657-60
71. Chung HS, Shin DH, Birt CM, et al. Chronic use of apraclonidine decreases its moderation of post-laser intraocular pressure spikes. Ophthalmology 1997;104:1921-5 (Pubitemid 28100352)
72. Araie M, Ishi K. Effects of apraclonidine on intraocular pressure and blood-aqueous barrier permeability after phacoemulsification and intraocular lens implantation. Am J Ophthalmol 1993 Jul; 116(1):67-71 (Pubitemid 23198485)
73. Robin AL. Effect of topical apraclonidine on the frequency of intraocular pressure elevations after combined extrćpsular ct́ract extraction and trabeculectomy. Ophthalmology 1993 May; 100(5):628-33 (Pubitemid 23143882)
74. Silverstone DE, Brint SF, Olander KW, et al. Prophylactic use of apraclonidine for intraocular pressure increase after Nd: YAG capsulotomies. Am J Ophthalmol 1992 Apr; 113(4):401-5
75. Araujo SV, Bond JB, Wilson RP, et al. Long term effect of apraclonidine. Br J Ophthalmol 1995;79:1098-101 (Pubitemid 26002683)
76. Lin SL, Liang SS. Evaluation of adverse reactions of apraclonidine hydrochloride ophthalmic solution. J Ocul Pharmacol Ther 1995 Fall; 11(3):267-78
77. Robin AL. Short-termeffects of unilateral 1%apraclonidine therapy. Arch Ophthalmol 1988 Jul; 106(7):912-5
78. Jampel HD, Robin AL, Quigley HA, et al. Apraclonidine: a one-week dose-response study. Arch Ophthalmol 1988 Aug; 106(8):1069-73
79. Britt MT, Burnstine MA. Iopidine allergy causing lower eyelid ectropion progressing to cicatricial entropion. Br J Ophthalmol 1999 Aug; 83(8):992-3 (Pubitemid 29376045)
80. Armisen M, Vidal C, Quintans R, et al. Allergic contact dermatitis from apraclonidine. Contact Dermatitis 1998 Oct; 39(4):193 (Pubitemid 28490979)
81. Feibel RM. High incidence of topical allergic reactions to 1% apraclonidine. Arch Ophthalmol 1995 Dec; 113(12):1579-80
82. Silvestre JF, Carnero L, Ramón R, et al. Allergic contact dermatitis from apraclonidine in eyedrops. Contact Dermatitis 2001 Oct; 45(4):251 (Pubitemid 32955032)
83. Thompson CD, Vachaspati PR, Kolis SP, et al. A proposed mechanism for p-aminoclonidine allergenicity based on its relative oxidative lability. Chem Res Toxicol 1997;10:1032-6 (Pubitemid 27418020)
84. Butler P, Mannschreck M, Lin S, et al. Clinical experience with the long-term use of 1% apraclonidine: incidence of allergic reactions. Arch Ophthalmol 1995 Mar; 113(3):293-6
85. Wilkerson M, Lewis RA, Shields MB. Follicular conjunctivitis associated with apraclonidine. Am J Ophthalmol 1991 Jan 15; 111(1):105-6
86. Robin AL, Ritch R, Shin D, et al. Topical apraclonidine hydrochloride in eyes with poorly controlled glaucoma. The Apraclonidine Maximum Tolerated Medical Therapy Study Group. Trans Am Ophthalmol Soc 1995;93:421-38; discussion 439-41
87. Toris CB, Gleason ML, Camras CB, et al. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol 1995 Dec; 113(12):1514-7
88. Barnes SD, Campagna JA, Dirks MS, et al. Control of intraocular pressure elevations after argon laser trabeculoplasty: comparison of brimonidine 0.2% to apraclonidine 1.0%. Ophthalmology 1999 Oct; 106(10):2033-7
89. Ma YR, Lee BH, Yang KJ, et al. The efficacy of 0.2% brimonidine for preventing intraocular pressure rise following argon laser trabeculoplasty. Korean J Ophthalmol 1999 Dec; 13(2):78-84
90. Gordon RN, Liebmann JM, Greenfield DS, et al. Lack of cross-reactive allergic response to brimonidine in patients with known apraclonidine allergy. Eye 1998;12:697-700 (Pubitemid 28418579)
91. Williams GC, Orengo-Nania S, Gross RL. Incidence of brimonidine allergy in patients previously allergic to apraclonidine. J Glaucoma 2000 Jun; 9(3):235-8 (Pubitemid 32429364)
92. Osborne SA, Montgomery DM, Morris D, et al. Alphǵn allergy may increase the propensity for multiple eye-drop allergy. Eye (Lond) 2005 Feb; 19(2):129-37 (Pubitemid 40309497)
93. Schuman JS, Horwitz B, Choplin NT, et al. A l-year study of brimonidine twice daily in glaucoma and ocular hypertension: a controlled, randomized, multicenter clinical trial. Arch Ophthalmol 1997;115:847-52
94. Serle JB. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III. Surv Ophthalmol 1996;41 Suppl. 1: S39-47 (Pubitemid 26422592)
95. LeBlanc RP. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2. Ophthalmology 1998;105:1960-7 (Pubitemid 28509740)
96. Hegde V, Robinson R, Dean F, et al. Drug-induced ectropion: what is best practice? Ophthalmology 2007 Feb; 114(2):362-6 (Pubitemid 46161816)
97. Aristodemou P, Baer R. Reversible cicatricial ectropion precipitated by topical brimonidine eye drops. Ophthal Plast Reconstr Surg 2008 Jan-Feb; 24(1):57-8
98. Scruggs JT, Whiteside-Michel J, Brodsky MC. The teardrop sign: a rare dermatological reaction to brimonidine. Br J Ophthalmol 2000 Jun; 84(6):671-2 (Pubitemid 30339329)
99. Sodhi PK, Verma L, Rt́n J. Dermatological side effects of brimonidine: a report of three cases. J Dermatol 2003 Sep; 30(9):697-700 (Pubitemid 37229271)
100. Bordel-Gómez MT, Sánchez-Estella J, Santos-Durán JC. Unilateral allergic contact dermatitis of the eyelid caused by Iopimax. Actas Dermosifiliogr 2009 Dec; 100(10):917-8
101. Whitson JT, Ochsner KI, Moster MR, et al. The safety and intraocular pressure-lowering efficacy of brimonidine tartrate 0.15% preserved with polyquaternium-1. Ophthalmology 2006 Aug; 113(8):1333-9 (Pubitemid 44108169)
102. Sugrue MF, Mallorga P, Schwam H, et al. A comparison of L-671, 152 and MK-927, two topically effective ocular hypotensive carbonic anhydrase inhibitors, in experimental animals. Curr Eye Res 1990 Jun; 9(6):607-15 (Pubitemid 20316720)
103. Silver LH. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open angle glaucoma and ocular hypertension. Am J Ophthalmol 1998 Sep; 126(3):400-8
104. Barnebey H, Kwok SY. Patients' acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting. Clin Ther 2000 Oct; 22(10):1204-12
105. DeSantis L. Preclinical overview of brinzolamide. Surv Ophthalmol 2000 Jan; 44 Suppl. 2: S119-29
106. Strahlman E, Tipping R, Vogel R. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International Dorzolamide Study Group. Arch Ophthalmol 1995 Aug; 113(8):1009-16
107. Rosenberg LF, Krupin T, Tang LQ, et al. Combination of systemic acetazolamide and topical dorzolamide in reducing intraocular pressure and aqueous humor formation. Ophthalmology 1998;105:88-93 (Pubitemid 28070606)
108. Epstein R, Brown SV, Dennis RF, et al. Combination of systemic acetazolamide and topical dorzolamide. Ophthalmology 1998;105:1581-2 (Pubitemid 28513500)
109. Lippa EA, Aasved H, Airaksinen PJ, et al. Multiple-dose, dose-response relationship for the topical carbonic anhydrase inhibitor MK-927. Arch Ophthalmol 1991 Jan; 109(1):46-9
110. Kluger N, Guillot B, Raison-Peyron N. Systemic contact dermatitis to dorzolamide eye drops. Contact Dermatitis 2008 Mar; 58(3):167-8 (Pubitemid 351248549)
111. Linares Mt́ T, Pardo Sánchez J, de la Cuadra Oyanguren J. Contact dermatitis caused by allergy to dorzolamide. Contact Dermatitis 2005 Feb; 52(2):111-2 (Pubitemid 40343866)
112. Shimd́ M, Higaki Y, Kẃshima M. Allergic contact dermatitis due to dorzolamide eyedrops. Contact Dermatitis 2001 Jul; 45(1):52
113. Aalto-Korte K. Contact allergy to dorzolamide eyedrops. Contact Dermatitis 1998 Oct; 39(4):206 (Pubitemid 28490991)
114. Delaney YM, Salmon JF, Mossa F, et al. Periorbital dermatitis as a side effect of topical dorzolamide. Br J Ophthalmol 2002 Apr; 86(4):378-80 (Pubitemid 34293282)
115. Munshi V, Ahluwalia H. Erythema multiforme after use of topical dorzolamide. J Ocul Pharmacol Ther 2008 Feb; 24(1):91-3 (Pubitemid 351156634)
116. Asensio-Sánchez VM. Toxic epidermal necrolysis following dorzolamide eyedrops. An Med Interna 2008 Jan; 25(1):47-8 (Pubitemid 351520801)
117. Adamsons IA, Polis A, Ostrov CS, et al. Two-year safety study of dorzolamide as monotherapy and with timolol and pilocarpine. Dorzolamide Safety Study Group. J Glaucoma 1998;7:395-401 (Pubitemid 30247084)
118. Gupta R, Vernon SA. An unusual appeŕnce of limbal conjunctival follicles in a patient on brimonidine and dorzolamide. Eye (Lond) 2005 Mar; 19(3):356-8 (Pubitemid 40484836)
119. Schnyder CC, Tran VT, Mermoud A, et al. Sterile mucopurulent conjunctivitis associated with the use of dorzolamide eyedrops. Arch Ophthalmol 1999 Oct; 117(10):1429-31 (Pubitemid 30029362)
120. Mancuso G, Berdondini RM. Allergic contact blepharoconjunctivitis from dorzolamide. Contact Dermatitis 2001 Oct; 45(4):243 (Pubitemid 32955027)
121. Noguchi T, Kẃsaki S, Mizoue S, et al. Mechanism of blurred vision after brinzolamide instillation. Nippon Ganka Gakkai Zasshi 2010 Apr; 114(4):369-73
122. Wirtitsch MG, Findl O, Heinzl H, et al. Effect of dorzolamide hydrochloride on central corneal thickness in humans with cornea guttt́. Arch Ophthalmol 2007 Oct; 125(10):1345-50 (Pubitemid 47606598)
123. Epstein RJ, Brown SV, Konowal A. Endothelial changes associated with topical dorzolamide do appear to be significant [letter]. Arch Ophthalmol 2004 Jul; 122(7):1089
124. Tanimura H, Minamoto A, Nŕi A, et al. Corneal edema in glaucoma patients after the addition of brinzolamide 1% ophthalmic suspension. Jpn J Ophthalmol 2005 Jul-Aug; 49(4):332-3 (Pubitemid 41264815)
125. Zhao JC, Chen T. Brinzolamide induced reversible corneal decompensation. Br J Ophthalmol 2005 Mar; 89(3):389-90 (Pubitemid 40327632)
126. Konowal A, Morrison JC, Brown SV, et al. Irreversible corneal decompensation in patients treated with topical dorzolamide. Am J Ophthalmol 1999 Apr; 127(4):403-6 (Pubitemid 29165473)
127. Domingo Gordo B, Urcelay Segura JL, Conejero Arroyo J, et al. Corneal decompensation in patients with endothelial compromise treated with topical dorzolamide. Arch Soc Esp Oftalmol 2002 Mar; 77(3):139-44
128. Kohlhaas M, Mammen A, Richard G. Change in corneal sensitivity after topical dorzolamide administration: a compŕtive study. Ophthalmologe 1997 Jun; 94(6):424-7 (Pubitemid 27299682)
129. Ammar DA, Kahook MY. The effects of combination glaucoma medications on ocular surface epithelial cells. Adv Ther 2009 Oct; 26(10):970-5
130. Zimmerman TJ, Wheeler TM. Miotics: side effects and ways to avoid them. Ophthalmology 1982;89:76-80 (Pubitemid 12173512)
131. Edwards RS. A compŕtive study of Ocusert Pilo 40, intensive pilocarpine and low-dose pilocarpine in the initial treatment of primary acute angle-closure glaucoma. Curr Med Res Opin 1997;13:501-9 (Pubitemid 27199152)
132. Johnson DH, Kenyon KR, Epstein DL, et al. Corneal changes during pilocarpine gel therapy. Am J Ophthalmol 1986;101:13-5 (Pubitemid 16128719)
133. Johnson DH, Epstein DL, Allen RC, et al. A one-year multicenter clinical trial of pilocarpine gel. Am J Ophthalmol 1984;97:723-9 (Pubitemid 14082959)
134. Helton J, Storrs FJ. Pilocarpine allergic contact and photocontact dermatitis. Contact Dermatitis 1991 Aug; 25(2):133-4
135. Cusano F, Luciano S, Capozzi M, et al. Contact dermatitis from pilocarpine. Contact Dermatitis 1993 Aug; 29(2):99 (Pubitemid 23226513)
136. Ortiz FJ, Postigo C, Ivars J, et al. Allergic contact dermatitis from pilocarpine and thimerosal. Contact Dermatitis 1991 Sep; 25(3):203-4
137. Holmberg A. Eczema of the eyelids caused by pilocarpine. Acta Ophthalmol (Copenh) 1955;33(4):371-5
138. Wright P. Squamous metaplasia or epidermalization of the conjunctiva as an adverse reaction to topical medication. Tram Ophthalmol Soc U K 1979;99:244-6 (Pubitemid 10074863)
139. Gerstenberger A, Marquardt R. Goblet cell density modified by pilocarpine. Fortschr Ophthalmol 1986;83(1):46-50 (Pubitemid 16143476)
140. Jackson WB. Differentiating conjunctivitis of diverse origins. Surv Ophthalmol 1993 Jul-Aug; 38 Suppl.: 91-104 (Pubitemid 23239416)
141. Tauber J, Melamed S, Foster CS. Glaucoma in patients with ocular cicatricial pemphigoid. Ophthalmology 1989 Jan; 96(1):33-7 (Pubitemid 19041324)
142. Pouliquen Y, Patey A, Foster CS, et al. Drug-induced cicatricial pemphigoid affecting the conjunctiva: light and electron microscopic features. Ophthalmology 1986 Jun; 93(6):775-83 (Pubitemid 16068348)
143. Schwab IR, Linberg JV, Gioia VM, et al. Foreshortening of the inferior conjunctival fornix associated with chronic glaucoma medications. Ophthalmology 1992 Feb; 99(2):197-202
144. Drance SM. A comparison of the effects of betaxolol, timolol, and pilocarpine on visual function in patients with open-angle glaucoma. J Glaucoma 1998;7:247-52 (Pubitemid 29149817)
145. Radian AB. Erosive marginal keratitis due to pilocarpine allergy. Oftalmologia 1999;47(2):83-4
146. Massry GG, Assil KK. Pilocarpine-associated allograft rejection in postkeratoplasty patients. Cornea 1995 Mar; 14(2):202-5
147. Coles WH. Pilocarpine toxicity: effects on the rabbit corneal endothelium. Arch Ophthalmol 1975 Jan; 93(1):36-41
148. Chapter 30. Prostaglandins and hypotensive lipids. In: Allingham R, Damji K, Freedman S, et al., editors. Shield's textbook of glaucoma. 5th ed. Philadelphia (PA): Lippincott Williams and Wilkins, 2005:472-3
149. Nǵsubrḿnian S, Sheth GP, Hitchings RA, et al. Intraocular pressure-reducing effect of PhXA41 in ocular hypertension: comparison of dose regimens. Ophthalmology 1993 Sep; 100(9):1305-11 (Pubitemid 23274022)
150. Racz P, Ruzsonyi MR, Nagy ZT, et al. Maintained intraocular pressure reduction with once-a-day application of a new prostaglandin F2 alpha ńlogue (PhXA41): an in-hospital, placebo-controlled study. Arch Ophthalmol 1993 May; 111(5):657-61 (Pubitemid 23143175)
151. Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% lt́noprost applied once daily, evening or morning: a comparison with timolol. Scandinavian Lt́noprost Study Group. Ophthalmology 1995 Dec; 102(12):1743-52 (Pubitemid 26004426)
152. Wand M, Ritch R, Isbey Jr EK, et al. Lt́noprost and periocular skin color changes. Arch Ophthalmol 2001 Apr; 119(4):614-5 (Pubitemid 32293569)
153. Kook MS, Lee K. Increased eyelid pigmentation associated with use of lt́noprost. Am J Ophthalmol 2000 Jun; 129(6):804-6 (Pubitemid 30604165)
154. Chien KH, Lu DW, Chen JT. Extensive facial skin pigmentation after lt́noprost treatment. Cutan Ocul Toxicol 2009;28(4):185-7
155. Pérez-Rodríguez E, González-Pérez R, Poza P, et al. Contact dermatitis caused by lt́noprost-containing eye drops with good tolerance to bimatoprost eye drops. Contact Dermatitis 2008 Jun; 58(6):370-1 (Pubitemid 351733059)
156. Lai CH, Lai IC, Chi CC. Allergic contact dermatitis caused by lt́noprost ophthalmic solution. Eur J Ophthalmol 2006 Jul-Aug; 16(4):627-9
157. Jerstad KM, Warshaw E. Allergic contact dermatitis to lt́noprost. Am J Contact Dermat 2002 Mar; 13(1):39-41
158. Sodhi PK, Verna L, Rt́n SK. Contact dermatitis from topical bimatoprost. Contact Dermatitis 2004;50:50 (Pubitemid 38491352)
159. Morales J, Shihab ZM, Brown SM, et al. Herpes simplex virus dermatitis in patients using lt́noprost. Am Ophthalmol 2001 Jul; 132(1):114-6 (Pubitemid 32600902)
160. Wand M. Lt́noprost and hyperpigmentation of eyelashes. Arch Ophthalmol 1997;115:1206-8
161. Reynolds A, Murray PI, Colloby PS. Darkening of eyelashes in a patient treated with lt́noprost. Eye 1998;12:741-3 (Pubitemid 28418589)
162. Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical lt́noprost. Am J Ophthalmol 1997;124:544-7 (Pubitemid 27425878)
163. Bito LZ. Prostaglandins: a new approach to glaucoma mńgement with a new, intriguing side effect. Surv Ophthalmol 1997;41 Suppl. 2: S1-14
164. Woo TL, Francis IC. Intermittent blurred vision and trichomegaly due to lt́noprost. Clin Exp Ophthalmol 2001 Aug; 29(4):272-3 (Pubitemid 32791448)
165. Mansberger SL, Cioffi GA. Eyelash formation secondary to lt́noprost treatment in a patient with alopecia. Arch Ophthalmol 2000 May; 118(5):718-9 (Pubitemid 30327353)
166. Rulo AH, Greve EL, Hoyng PF. Additive effect of lt́noprost, a prostaglandin F2a ńlogue, and timolol patients with elevated intraocular pressure. Br J Ophthalmol 1994;78:899-902
167. Widengard I, Maepea O, Alm A. Effects of lt́noprost and dipivefrin, alone or combined, on intraocular pressure and on blood-aqueous barrier permeability. Br J Ophthalmol 1998;82:404-6 (Pubitemid 28177151)
168. Fristrom B. A 6-month, randomized, double-masked comparison of lt́noprost with timolol in patients with open angle glaucoma or ocular hypertension. Acta Ophthalmol Stand 1996;74:140-4 (Pubitemid 26146617)
169. Watson P, Stjernschantz J. A six-month, randomized, double-masked study comparing lt́noprost with timolol open-angle glaucoma and ocular hypertension. The Lt́noprost Study Group. Ophthalmology 1996 Jan; 103(1):126-37 (Pubitemid 26046169)
170. Camras CB. Comparison of lt́noprost and timolol patients with ocular hypertension and glaucoma: a sixmonth masked, multicenter trial in the United States. The United States Lt́noprost Study Group. Ophthalmology 1996 Jan; 103(1):138-47 (Pubitemid 26046170)
171. Lark KK, Pasha AS, Yan X, et al. The effect of lt́noprost and brimonidine on rabbit subconjunctival fibroblasts. J Glaucoma 1999 Feb; 8(1):72-6
172. Moreno M, Villena A, Cb́rga C, et al. Impression cytology of the conjunctival epithelium after antiglaucomatous treatment with lt́noprost. Eur J Ophthalmol 2003 Jul; 13(6):553-9 (Pubitemid 38208839)
173. Stefan C, Dumitrica DM. Ocular surface dysfunction in glaucoma. Oftalmologia 2008;52(3):114-9
174. Mietz H, Esser JM, Welsandt G, et al. Lt́noprost stimulates secretion of matrix metalloproteinases in tenon fibroblasts both in vitro and in vivo. Invest Ophthalmol Vis Sci 2003 Dec; 44(12):5182-8 (Pubitemid 37475387)
175. Mietz H, Schlötzer-Schrehardt U, Strassfeld C, et al. Effect of lt́noprost and timolol on the histopathology of the rabbit conjunctiva. Invest Ophthalmol Vis Sci 2001 Mar; 42(3):679-87 (Pubitemid 32206908)
176. Wand M, Gilbert CM, Liesegang TJ. Lt́noprost and herpes simplex keratitis. Am J Ophthalmol 1999;127:602-4
177. Schumer RA, Camras CB, Mandahl AK. Putative side effects of prostaglandin ńlogs [abstract]. Surv Ophthalmol 2002 Aug; 47 Suppl. 1: S219
178. Kroll DM, Schuman JS. Reactivation of herpes simplex virus keratitis after initiating bimatoprost treatment for glaucoma. Am J Ophthalmol 2002 Mar; 133(3):401-3 (Pubitemid 34171592)
179. Villegas VM, Díaz L, Izquierdo NJ. Herpetic keratitis in a patient who used two different prostaglandin ńlogue ophthalmic solutions: a case report. P R Health Sci J 2008 Dec; 27(4):348-9
180. Ekatomatis P. Herpes simplex dendritic keratitis after treatment with lt́noprost for primary open angle glaucoma. Br J Ophthalmol 2001 Aug; 85(8):1008-9 (Pubitemid 32706180)
181. Asensio Sánchez VM. Recurrent corneal keratitis associated with the use of lt́noprost [letter]. Arch Soc Esp Oftalmol 2001 May; 76(5):277
182. Dios Castro E, Maquet Dusart JA. Lt́noprost-associated recurrent herpes simplex keratitis. Arch Soc Esp Oftalmol 2000 Nov; 75(11):775-8
183. Kothari MT, Mehta BK, Asher NS, et al. Recurrence of bilateral herpes simplex virus keratitis following bimatoprost use. Indian J Ophthalmol 2006 Mar; 54(1):47-8 (Pubitemid 43363579)
184. Kaufman HE, Vamell ED, Thompson HW. Lt́noprost increases the severity and recurrence of herpetic keratitis in the rabbit. Am J Ophthalmol 1999;127:531-6 (Pubitemid 29215763)
185. Sudesh S, Cohen EJ, Rapuano CJ, et al. Corneal toxicity associated with lt́noprost. Arch Ophthalmol 1999;117:539-40
186. Wistrand PJ, Stjernschantz J, Olsson K. The incidence and time-course of lt́noprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol 1997 Feb; 41 Suppl. 2: S129-38 (Pubitemid 27154537)
187. McCarey BE, Kapik BM, Kane FE. Low incidence of iris pigmentation and eyelash changes in 2 randomized clinical trials with unoprostone isopropyl 0.15%. Ophthalmology 2004 Aug; 111(8):1480-8 (Pubitemid 39030799)
188. Pappas RM, Pusin S, Higginbotham EJ. Evidence of early change in iris color with lt́noprost use. Arch Ophthalmol 1998 Aug; 116(8):1115-6 (Pubitemid 29101841)
189. Yḿmoto T, Kitźwa Y. Iris-color change developed after topical isopropyl unoprostone treatment. J Glaucoma 1997 Dec; 6(6):430-2
190. Lindsey JD, Jones HL, Hewitt EG, et al. Induction of tyrosinase gene transcription in human iris organ cultures exposed to lt́noprost. Arch Ophthalmol 2001 Jun; 119(6):853-60 (Pubitemid 32530314)
191. Stjernschantz JW, Albert DM, Hu DN, et al. Mechanism and clinical significance of prostaglandin-induced iris pigmentation. Surv Ophthalmol 2002 Aug; 47 Suppl. 1: S162-75 (Pubitemid 35232231)